The export originated from Filament’s Vancouver facility, intended for the University of California San Francisco (UCSF) translational psychedelic research program (TrPR) to be used in their expected phase 1 FDA trial and attendant clinical trials.
“This is an important milestone for Filament as we have demonstrated our ability to transport a controlled substance — in this case standardized psilocybin extract — for our own research purposes. It also opens the door to working with other international licensed research sites. We believe that this is the first transborder shipment of naturally-extracted GMP psilocybin — an achievement which validates our regulatory team’s work and affirms our ability to work closely with government agencies in Canada and abroad,” said Benjamin Lightburn, chief executive officer of Filament Health.
Vancouver-based Filament Health is in the drug discovery and extraction technology business for psychedelics. Their principle sources of revenue are their extract technology, but also their extensive IP portfolio, as well as from the proceeds of their in-house GMP facility, and their dealer’s license for all natural psychedelics.
The shipment contains capsules with Filament’s formulation of 25 milligrams of psilocybin. The capsules are all Filament’s design and were built in house and delivered to TrPR through both Health Canada U.S. Drug Enforcement Administration import and export permits respectively.
This is the first move after Filament picked up their first patent for the extraction and standardization of natural psilcoybin on August 3, and after an amendment to their Health Canada dealer’s license, acquired on July 29, giving them permission to work with psychedelics.
Full disclosure: Filament Health is an equity.guru marketing client.